Kjell Erik Julius Håkansson

Medicine & Life Sciences

1. 3-(2-(4-azidobenzamidino)ethyl)-5-hydroxyindole 7%
2. Absenteeism 12%
3. Adrenal Cortex Hormones 50%
4. Antidepressive Agents 17%
5. Anxiety 6%
6. Asthma 100%
7. Azithromycin 23%
8. Biological Products 9%
9. Bronchiectasis 24%
10. Cardiovascular Diseases 5%
11. Child 5%
12. Chronic Obstructive Pulmonary Disease 37%
13. Cohort Studies 47%
14. Coronavirus 22%
15. Costs and Cost Analysis 5%
16. Delivery of Health Care 7%
17. Denmark 8%
18. Depression 9%
19. Drive 9%
20. Education 6%
21. Eosinophils 11%
22. Hospital Mortality 9%
23. Hospitalization 9%
24. Hydroxychloroquine 38%
25. Hydroxymethylglutaryl-CoA Reductase Inhibitors 18%
26. Income 9%
27. Infections 5%
28. Inflammation 7%
29. Interleukin-5 10%
30. Meta-Analysis 8%
31. Mood Disorders 6%
32. Mortality 24%
33. Outpatients 14%
34. Patient Readmission 11%
35. Placebos 7%
36. Prescriptions 6%
37. Prospective Studies 6%
38. Quality of Life 6%
39. Randomized Controlled Trials 9%
40. Referral and Consultation 7%
41. Rheumatoid Arthritis 7%
42. Severe Acute Respiratory Syndrome 11%
43. Social Class 10%
44. Systematic Reviews 7%
45. Urokinase Plasminogen Activator Receptors 13%
46. Young Adult 23%